Abstract
Dementia with Lewy bodies (DLB) is the second most common form of degenerative dementia. However, it can be difficult to diagnose as it shares common features with both Alzheimer’s disease (AD) and Parkinson’s disease (PD). Early detection as well as accurate differentiation from other types of dementia are essential to inform management and treatment. Clinical diagnosis of DLB can be difficult, with up to 50% of cases being misdiagnosed (Walker et al., Lancet 386:1683–1697, 2015). The use of biomarkers, particularly imaging biomarkers, has greatly contributed to the accurate diagnosis of DLB. This chapter will give an overview of the contribution of PET and SPECT imaging modalities to the diagnosis of DLB and the better understanding of the underlying pathology. The areas covered include metabolic, amyloid, microglial activity, dopaminergic and cholinergic imaging in DLB. Some of these imaging methods are now well established and highly reliable at facilitating accurate diagnosis. In the future, others are likely to inform treatment or provide bases for the development of new drugs. New ligands are constantly being developed and are likely to focus on microglial activation and tau pathology in DLB.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The authors of this chapter calculated the values for DLB versus AD sensitivity and specificity based on Table 4 in (O’Brien et al. 2014), taking only those with a correct imaging diagnosis of dementia (58 18F-FDG PET and 48 SPECT), as these values were not reported in the paper explicitly.
References
Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA (1996) Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47(2):462–466
Atkinson J et al (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
Ballard C, Ziabreva I, Perry R, Larsen JP, O’Brien J, McKeith I et al (2006) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67(11):1931–1934. https://doi.org/10.1212/01.wnl.0000249130.63615.cc
Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(11):2321–2337. https://doi.org/10.1093/brain/123.11.2321
Barbas NR (2006) Cognitive, affective, and psychiatric features of Parkinson’s disease. Clin Geriatr Med 22(4):773–796. https://doi.org/10.1016/j.cger.2006.06.004
Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE (1999) Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia. Neurology 52(3):541. https://doi.org/10.1212/wnl.52.3.541
Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115(1):1–17. https://doi.org/10.1016/0022-510X(93)90061-3
Caminiti SP, Alongi P, Majno L, Volontè MA, Cerami C, Gianolli L et al (2017) Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur J Neurol 24(5):687–e26. https://doi.org/10.1111/ene.13269
Caminiti SP, Sala A, Iaccarino L, Beretta L, Pilotto A, Gianolli L et al (2019) Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimers Res Ther 11(1):20. https://doi.org/10.1186/s13195-019-0473-4
Cerami C, Iaccarino L, Perani D (2017) Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int J Mol Sci 18(5):993
Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O’Brien JT (2005) Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 32(10):1176–1185. https://doi.org/10.1007/s00259-005-1830-z
Colloby SJ, Pakrasi S, Firbank MJ, Perry EK, Piggott MA, Owens J et al (2006) In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia. NeuroImage 33(2):423–429. https://doi.org/10.1016/j.neuroimage.2006.07.026
Colloby SJ, McParland S, O’Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 135(9):2798–2808. https://doi.org/10.1093/brain/aws211
Donaghy PC, Firbank MJ, Thomas AJ, Lloyd J, Petrides G, Barnett N et al (2018) Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies. Mov Disord 33(7):1130–1138. https://doi.org/10.1002/mds.27403
Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79(12):1331–1338. https://doi.org/10.1136/jnnp.2007.127878
Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. Acta Neuropathol 57(2):239–242. https://doi.org/10.1007/BF00685397
Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 17(5):673–680
Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB et al (2012) EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 19(12):1487–1501. https://doi.org/10.1111/j.1468-1331.2012.03859.x
Firbank MJ, Lloyd J, O’Brien JT (2016) The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. Brain Imaging Behav 10(3):636–639. https://doi.org/10.1007/s11682-015-9434-0
Francis PT, Perry EK (2007) Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov Disord 22(S17):S351–S3S7. https://doi.org/10.1002/mds.21683
Galasko D, Katzman R, Salmon DP, Hansen L (1996) Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 31(2):166–175. https://doi.org/10.1006/brcg.1996.0040
Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P (1997) Motor and cognitive function in Lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 62(3):243–252. https://doi.org/10.1136/jnnp.62.3.243
Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C et al (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. JAMA Neurol 60(9):1218–1222. https://doi.org/10.1001/archneur.60.9.1218
Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J et al (2012) Brain amyloid and cognition in Lewy body diseases. Mov Disord 27(8):965–973. https://doi.org/10.1002/mds.25048
Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH (2016) PET radioligands reveal the basis of dementia in Parkinson’s disease and dementia with Lewy bodies. Neurodegener Dis 16(1–2):118–124. https://doi.org/10.1159/000441421
Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA et al (2014) Dementia with Lewy bodies: basis of cingulate island sign. Neurology 83(9):801–809. https://doi.org/10.1212/WNL.0000000000000734
Hayashi T, Mishina M, Sakamaki M, Sakamoto Y, Suda S, Kimura K (2019) Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT. Ann Nucl Med 33(8):579–585. https://doi.org/10.1007/s12149-019-01367-4
Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S et al (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 162(2):247–256. https://doi.org/10.1006/exnr.2000.7342
Hirohata M, Ono K, Morinaga A, Yamada M (2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. Neuropharmacology 54(3):620–627. https://doi.org/10.1016/j.neuropharm.2007.11.010
Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M et al (2000) 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55(10):1575–1577. https://doi.org/10.1212/wnl.55.10.1575
Huang S-H, Chang C-C, Lui C-C, Chen N-C, Lee C-C, Wang P-W et al (2015) Cortical metabolic and nigrostriatal abnormalities associated with clinical stage-specific dementia with Lewy bodies. Clin Nucl Med 40(1):26–31. https://doi.org/10.1097/rlu.0000000000000620
Iaccarino L, Marelli S, Iannaccone S, Magnani G, Ferini-Strambi L, Perani D (2016) Severe brain metabolic decreases associated with REM sleep behavior disorder in dementia with Lewy bodies. J Alzheimers Dis 52:989–997
Iaccarino L, Sala A, Caminiti SP, Santangelo R, Iannaccone S, Magnani G et al (2018) The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. Cortex 108:13–24. https://doi.org/10.1016/j.cortex.2018.06.014
Iizuka T, Kameyama M (2016) Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies. Ann Nucl Med 30(6):421–429. https://doi.org/10.1007/s12149-016-1076-9
Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazui H et al (2001) Occipital glucose metabolism in dementia with Lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord 12(3):194–197. https://doi.org/10.1159/000051257
Iranzo A, Santamaría J, Valldeoriola F, Serradell M, Salamero M, Gaig C et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82(3):419–428. https://doi.org/10.1002/ana.25026
Ishii K, Imamura T, Sasaki M, Yamaji S, Kitagaki H, Hashimoto M et al (1998) Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 51(1):125–130
Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T et al (2007) Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer’s disease. J Nucl Med 48:704–711
Ishii K, Hosokawa C, Hyodo T, Sakaguchi K, Usami K, Shimamoto K et al (2015) Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition. Ann Nucl Med 29(1):78–83. https://doi.org/10.1007/s12149-014-0911-0
Jack CR Jr, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS et al (2019) The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain 142(10):3230–3242. https://doi.org/10.1093/brain/awz268
Jia J, Hu J, Huo X, Miao R, Zhang Y, Ma F (2019) Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer’s disease: a randomised, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 90(12):1347–1352. https://doi.org/10.1136/jnnp-2018-320199
Joling M, Vriend C, van der Zande JJ, Lemstra AW, van den Heuvel OA, Booij J et al (2018) Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson’s disease compared with dementia with Lewy bodies. NeuroImage Clin 19:130–136. https://doi.org/10.1016/j.nicl.2018.04.009
Joling M, Vriend C, Raijmakers PGHM, van der Zande JJ, Lemstra AW, Berendse HW et al (2019) Striatal DAT and extrastriatal SERT binding in early-stage Parkinson’s disease and dementia with Lewy bodies, compared with healthy controls: an 123I-FP-CIT SPECT study. NeuroImage Clin 22:101755. https://doi.org/10.1016/j.nicl.2019.101755
Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA et al (2012) Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 33(9):2091–2105. https://doi.org/10.1016/j.neurobiolaging.2011.09.024
Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG et al (2017) AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 81(1):58–67. https://doi.org/10.1002/ana.24825
Kasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K et al (2017) 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 44(3):358–365. https://doi.org/10.1007/s00259-016-3466-6
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55(3):306–319. https://doi.org/10.1002/ana.20009
Kobayashi S, Makino K, Hatakeyama S, Ishii T, Tateno M, Iwamoto T et al (2017) The usefulness of combined brain perfusion single-photon emission computed tomography, dopamine-transporter single-photon emission computed tomography, and 123I-metaiodobenzylguanidine myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Psychogeriatrics 17(4):247–255. https://doi.org/10.1111/psyg.12227
Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA (2008) Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4(1 Suppl 1):S67–S76. https://doi.org/10.1016/j.jalz.2007.11.016
Lee SH, Cho H, Choi JY, Lee JH, Ryu YH, Lee MS et al (2018) Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Mov Disord 33(2):262–272. https://doi.org/10.1002/mds.27252
Liguori C, Ruffini R, Olivola E, Chiaravalloti A, Izzi F, Stefani A et al (2019) Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: a brain [18F]FDG PET study. Parkinsonism Relat Disord 64:97–105. https://doi.org/10.1016/j.parkreldis.2019.03.017
Lim S, Katsifis A, Villemagne V, Best R, Jones G, Saling M et al (2009) The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50(10):1638–1645
Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L et al (2007) PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 130(10):2607–2615. https://doi.org/10.1093/brain/awm191
Mackenzie IRA (2000) Activated microglia in dementia with Lewy bodies. Neurology 55(1):132–134. https://doi.org/10.1212/wnl.55.1.132
Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C et al (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34(1):107–112. https://doi.org/10.1016/j.nbd.2008.12.008
Mak E, Donaghy PC, McKiernan E, Firbank MJ, Lloyd J, Petrides GS et al (2019) Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies. Neurobiol Aging 73:74–81. https://doi.org/10.1016/j.neurobiolaging.2018.09.004
Marquie M, Locascio JJ, Rentz DM, Becker JA, Hedden T, Johnson KA et al (2014) Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study. Alzheimers Res Ther 6(5):52. https://doi.org/10.1186/s13195-014-0052-7
Mazère J, Lamare F, Allard M, Fernandez P, Mayo W (2017) 123I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies. J Nucl Med 58:123–128
McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107(1):341–346. https://doi.org/10.1016/0304-3940(89)90843-4
McKeith IGGD, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP et al (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113–1124
McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop. Diagnosis and treatment. Neurology 53(5):902–905. https://doi.org/10.1212/wnl.53.5.902
McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al (2004) Dementia with Lewy bodies. Lancet Neurol 3(1):19–28. https://doi.org/10.1016/S1474-4422(03)00619-7
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB Consortium. Neurology 65(12):1863–1872. https://doi.org/10.1212/01.wnl.0000187889.17253.b1
McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6(4):305–313. https://doi.org/10.1016/S1474-4422(07)70057-1
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB Consortium. Neurology 89(1):88–100. https://doi.org/10.1212/wnl.0000000000004058
Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R et al (2019) Metabolic patterns across core features in dementia with Lewy bodies. Ann Neurol 85(5):715–725. https://doi.org/10.1002/ana.25453
Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L et al (2012) Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 83(11):1063–1070. https://doi.org/10.1136/jnnp-2012-302577
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G et al (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 49(3):390–398. https://doi.org/10.2967/jnumed.107.045385
Nedelska Z, Schwarz CG, Boeve BF, Lowe VJ, Reid RI, Przybelski SA et al (2015) White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging 36(6):2010–2017. https://doi.org/10.1016/j.neurobiolaging.2015.03.007
Nedelska Z, Josephs KA, Graff-Radford J, Przybelski SA, Lesnick TG, Boeve BF et al (2019) 18F-AV-1451 uptake differs between dementia with Lewy bodies and posterior cortical atrophy. Mov Disord 34(3):344–352. https://doi.org/10.1002/mds.27603
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z et al (2018) Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging 45(9):1509–1525. https://doi.org/10.1007/s00259-018-4035-y
Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357(9251):169–175. https://doi.org/10.1016/s0140-6736(00)03589-3
Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR (2017) Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. Clin Nucl Med 42(2):e96–e102. https://doi.org/10.1097/rlu.0000000000001477
O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D et al (2004) Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. JAMA Neurol 61(6):919–925. https://doi.org/10.1001/archneur.61.6.919
O’Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ et al (2008) Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. NeuroImage 40(3):1056–1063. https://doi.org/10.1016/j.neuroimage.2008.01.010
O’Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J et al (2009) Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194(1):34–39. https://doi.org/10.1192/bjp.bp.108.052050
O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C et al (2014) 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med 55:1959–1965
Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R et al (2009) Microglial activation and amyloid deposition in mild cognitive impairment. A PET study. Neurology 72(1):56–62. https://doi.org/10.1212/01.wnl.0000338622.27876.0d
Okizaki A, Nakayama M, Nakajima K, Katayama T, Uno T, Morikawa F et al (2017) Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB. Ann Nucl Med 31(10):758–763. https://doi.org/10.1007/s12149-017-1209-9
Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D et al (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7(2):69–79
Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22(6):273–280. https://doi.org/10.1016/S0166-2236(98)01361-7
Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E et al (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 122(8):1449–1468. https://doi.org/10.1093/brain/122.8.1449
Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S et al (2019) Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 46(8):1642–1651. https://doi.org/10.1007/s00259-019-04324-5
Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G et al (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112(5):677–692. https://doi.org/10.1007/s00702-004-0208-x
Power JHT, Blumbergs PC (2009) Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol 117(1):63–73. https://doi.org/10.1007/s00401-008-0438-3
Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45(3):358–368. https://doi.org/10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24(14):2097–2103. https://doi.org/10.1002/mds.22702
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al (2007) Imaging β-amyloid burden in aging and dementia. Neurology 68(20):1718–1725. https://doi.org/10.1212/01.wnl.0000261919.22630.ea
Sala A, Caminiti SP, Iaccarino L, Beretta L, Iannaccone S, Magnani G et al (2019) Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies. Hum Brain Mapp 40(15):4537–4550. https://doi.org/10.1002/hbm.24719
Samuel W, Alford M, Hofstetter CR, Hansen L (1997) Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 56(5):499–508. https://doi.org/10.1097/00005072-199705000-00006
Sarro L, Senjem ML, Lundt ES, Przybelski SA, Lesnick TG, Graff-Radford J et al (2016) Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain 139(10):2740–2750. https://doi.org/10.1093/brain/aww193
Shepherd CE, Thiel E, McCann H, Harding AJ, Halliday GM (2000) Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. JAMA Neurol 57(6):817–822. https://doi.org/10.1001/archneur.57.6.817
Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4):273–278. https://doi.org/10.1212/WNL.0b013e3181ab2b58
Shimada H, Hirano S, Sinotoh H, Ota T, Tanaka N, Sato K et al (2015) Dementia with Lewy bodies can be well-differentiated from Alzheimer’s disease by measurement of brain acetylcholinesterase activity—a [11C]MP4A PET study. Int J Geriatr Psychiatry 30(11):1105–1113. https://doi.org/10.1002/gps.4338
Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D et al (2016) Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease. Eur J Nucl Med Mol Imaging 43(1):184–192. https://doi.org/10.1007/s00259-015-3146-y
Shimizu S, Hirose D, Namioka N, Kanetaka H, Hirao K, Hatanaka H et al (2017a) Correlation between clinical symptoms and striatal DAT uptake in patients with DLB. Ann Nucl Med 31(5):390–398. https://doi.org/10.1007/s12149-017-1166-3
Shimizu S, Kanetaka H, Hirao K, Fukasawa R, Namioka N, Hatanaka H et al (2017b) Neuroimaging for diagnosing dementia with Lewy bodies: what is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer’s disease? Geriatr Gerontol Int 17(5):819–824. https://doi.org/10.1111/ggi.12794
Shimizu S, Namioka N, Hirose D, Kanetaka H, Hirao K, Hatanaka H et al (2017c) Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD. J Neurol Sci 377:50–54. https://doi.org/10.1016/j.jns.2017.03.040
Shirvan J, Clement N, Ye R, Katz S, Schultz A, Johnson KA et al (2019) Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. Neurology 93(5):e476–ee84. https://doi.org/10.1212/wnl.0000000000007855
Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD et al (2014) PET imaging of amyloid with Florbetapir F18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders. BMC Neurol 14:79. https://doi.org/10.1186/1471-2377-14-79
Siepel FJ, Dalen I, Grüner R, Booij J, Brønnick KS, Buter TC et al (2016) Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy bodies. Mov Disord 31(1):118–125. https://doi.org/10.1002/mds.26327
Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R et al (2018) Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 141(12):3415–3427. https://doi.org/10.1093/brain/awy265
Szpak GM, Lechowicz W, Lewandowska E, Bertrand E, Wierzba-Bobrowicz T, Gwiazda E et al (2001) Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer’s disease and Lewy body variant of Alzheimer’s disease. Quantitative study. Folia Neuropathol 39(3):181–192
Thomas AJ, Attems J, Colloby SJ, O’Brien JT, McKeith I, Walker R et al (2017) Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 88(3):276–283. https://doi.org/10.1212/WNL.0000000000003512
Thomas AJ, Donaghy P, Roberts G, Colloby SJ, Barnett NA, Petrides G et al (2019) Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med 49(3):396–402. https://doi.org/10.1017/S0033291718000995
Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E et al (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54(2):407. https://doi.org/10.1212/wnl.54.2.407
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G et al (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52(8):1210–1217
Walker Z, Rodda J (2011) Dopaminergic imaging: clinical utility now and in the future. Int Psychogeriatr 23(S2):S32–S40. https://doi.org/10.1017/S1041610211000883
Walker RWH, Walker Z (2009) Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 24(S2):S754–S7S9. https://doi.org/10.1002/mds.22591
Walker Z, Costa DC, Janssen AG, Walker RWH, Livingstone G, Katona CLE (1997) Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography. Eur J Nucl Med 24(6):609–614. https://doi.org/10.1007/BF00841397
Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T et al (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73(2):134–140. https://doi.org/10.1136/jnnp.73.2.134
Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E et al (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. A comparison. Neurology 62(9):1568–1572. https://doi.org/10.1212/01.wnl.0000123248.39847.1d
Walker Z, Jaros E, Walker RWH, Lee L, Costa DC, Livingston G et al (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78(11):1176–1181. https://doi.org/10.1136/jnnp.2006.110122
Walker Z, Possin KL, Boeve BF, Aarsland D (2015a) Lewy body dementias. Lancet 386(10004):1683–1697. https://doi.org/10.1016/S0140-6736(15)00462-6
Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M et al (2015b) Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. Br J Psychiatry 206(2):145–152. https://doi.org/10.1192/bjp.bp.114.148643
Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T et al (2016) Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology 87(10):1045–1051. https://doi.org/10.1212/WNL.0000000000003076
Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla AJ et al (2017) (18)F-FDG PET in posterior cortical atrophy and dementia with Lewy bodies. J Nucl Med 58(4):632–638. https://doi.org/10.2967/jnumed.116.179903
Zheng G, Dwoskin LP, Crooks PA (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8(4):E682–EE92. https://doi.org/10.1208/aapsj080478
Ziebell M, Andersen BB, Pinborg LH, Knudsen GM, Stokholm J, Thomsen G et al (2013) Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med 54:1072–1076
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zabihi, S., Whitfield, T., Walker, Z. (2021). SPECT/PET Findings in Dementia with Lewy Bodies. In: Dierckx, R.A.J.O., Otte, A., de Vries, E.F.J., van Waarde, A., Leenders, K.L. (eds) PET and SPECT in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-53168-3_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-53168-3_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53167-6
Online ISBN: 978-3-030-53168-3
eBook Packages: MedicineMedicine (R0)